The role of chemokines and chemokine receptors in multiple sclerosis

被引:77
作者
Cui, Li-Yuan [1 ,2 ]
Chu, Shi-Feng [1 ,2 ]
Chen, Nai-Hong [1 ,2 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, State Key Lab Bioact Subst & Funct Nat Med, Inst Mat Med, Beijing 100050, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Neurosci Ctr, Beijing 100050, Peoples R China
基金
北京市自然科学基金; 中国国家自然科学基金;
关键词
Chemokines; Chemokine receptors; Multiple sclerosis; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; CENTRAL-NERVOUS-SYSTEM; ANIMAL-MODELS; LEUKOCYTE RECRUITMENT; GENE POLYMORPHISM; DISEASE-ACTIVITY; UP-REGULATION; WHITE-MATTER; CCL20; FRACTALKINE;
D O I
10.1016/j.intimp.2020.106314
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Multiple sclerosis (MS) is a chronic inflammatory disease that is characterized by leukocyte infiltration and subsequent axonal damage, demyelinating inflammation, and formation of sclerosing plaques in brain tissue. The results of various studies in patients indicate that autoimmunity and inflammation make an important impact on the pathogenesis of MS. Chemokines are key mediators of inflammation development and cell migration, mediating various immune cell responses, including chemotaxis and immune activation, and are important in immunity and inflammation, therefore we focus on chemokines and their receptors in multiple sclerosis. In this article, we summarize the study of the role of prominent chemokines and their receptors in MS patients and MS animal modelsand discuss their potential significance in inflammatory injury and repair of MS. We have also summarized the progress in the treatment of multiple sclerosis antagonists in recent years with chemokine receptors as targets.
引用
收藏
页数:11
相关论文
共 129 条
  • [1] Natural and induced immunization against CCL20 ameliorate experimental autoimmune encephalitis and may confer protection against multiple sclerosis
    Abraham, Michal
    Karni, Arnon
    Mausner-Fainberg, Karin
    Weiss, Ido D.
    Peled, Amnon
    [J]. CLINICAL IMMUNOLOGY, 2017, 183 : 316 - 324
  • [2] Current status of chemokine receptor inhibitors in development
    Allegretti, Marcello
    Cesta, Maria Candida
    Garin, Alexandre
    Proudfoot, Amanda E. I.
    [J]. IMMUNOLOGY LETTERS, 2012, 145 (1-2) : 68 - 78
  • [3] Chemokine: Receptor structure, interactions, and antagonism
    Allen, Samantha J.
    Crown, Susan E.
    Handel, Tracy M.
    [J]. ANNUAL REVIEW OF IMMUNOLOGY, 2007, 25 : 787 - 820
  • [4] Structural refinement and prediction of potential CCR2 antagonists through validated multi-QSAR modeling studies
    Amin, Sk Abdul
    Adhikari, Nilanjan
    Baidya, Sandip Kumar
    Gayen, Shovanlal
    Jha, Tarun
    [J]. JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2019, 37 (01) : 75 - 94
  • [5] [Anonymous], 2017, MULTIPLE SCLEROSIS P
  • [6] [Anonymous], [No title captured]
  • [7] Chemokines and atherosclerosis: focus on the CX3CL1/CX3CR1 pathway
    Apostolakis, Stavros
    Spandidos, Demetrios
    [J]. ACTA PHARMACOLOGICA SINICA, 2013, 34 (10) : 1251 - 1256
  • [8] Fractalkine Gene Receptor Polymorphism in Patients With Multiple Sclerosis
    Arli, Berna
    Irkec, Ceyla
    Menevse, Sevda
    Yilmaz, Akin
    Alp, Ebru
    [J]. INTERNATIONAL JOURNAL OF NEUROSCIENCE, 2013, 123 (01) : 31 - 37
  • [9] Rat brain pericyte cell lines expressing β2-adrenergic receptor, angiotensin II receptor type 1A, klotho, and CXCR4 mRNAs despite having endothelial cell markers
    Asashima, T
    Iizasa, H
    Terasaki, T
    Nakashima, E
    [J]. JOURNAL OF CELLULAR PHYSIOLOGY, 2003, 197 (01) : 69 - 76
  • [10] ECL1i, d(LGTFLKC), a novel, small peptide that specifically inhibits CCL2-dependent migration
    Auvynet, Constance
    de Chanville, Camille Baudesson
    Hermand, Patricia
    Dorgham, Karim
    Piesse, Christophe
    Pouchy, Charlotte
    Carlier, Ludovic
    Poupel, Lucie
    Barthelemy, Sandrine
    Felouzis, Virginie
    Lacombe, Claire
    Sagan, Sandrine
    Salomon, Benoit
    Deterre, Philippe
    Sennlaub, Florian
    Combadiere, Christophe
    [J]. FASEB JOURNAL, 2016, 30 (06) : 2370 - 2381